Market Overview
The global Keytruda (pembrolizumab) market is experiencing growth driven by checkpoint immunotherapy dominance, cancer indications expansion, and clinical success documentation. The Keytruda market is projected to exceed USD 32.8 billion through 2030, fueled by pembrolizumab approvals exceeding 25 indications, patient populations exceeding 1 million annually, and breakthrough...
Bangla